Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how CHAARTED and STAMPEDE impacted his treatment for patients with metastatic hormone sensitive prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.
How did CHAARTED and STAMPEDE impact your treatment of metastatic hormone sensitive prostate cancer patients?
